Editorials

Trump blames free riding foreign states for high US drug prices

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k1088 (Published 16 March 2018) Cite this as: BMJ 2018;360:k1088
  1. Donald W Light, professor of comparative healthcare policy1,
  2. Arthur L Caplan, Mitty professor2
  1. 1Rowan University-School of Osteopathic Medicine, Cherry Hill, NJ, USA
  2. 2Division of Medical Ethics, New York University School of Medicine, New York City, USA
  1. Correspondence to: D W Light lightdo{at}rowan.edu

When economic experts give bad advice, everyone suffers

Why are drug prices in the US so high? In a recent and long awaited white paper, the US Council of Economic Advisers provides erroneous answers to a problem that is threatening household, state, and national budgets.1

The advisers tell the White House and Congress that other affluent countries in the Organisation for Economic Cooperation and Development (OECD) force drug companies to overcharge Americans because “centralized pricing” in these countries sets prices so low that they act as “foreign free riders,” who allegedly fail to pay for the cost of research and development. As explained in The BMJ years ago and updated here, industry leaders, the US trade association for pharmaceuticals, and the commissioner of the FDA made this claim in the early 2000s to redirect widespread anger at high prices.23 Independent reports and evidence then and now indicate that prices for patented drugs in other affluent countries such as the UK and Canada do pay for research and development.345 Higher prices …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription